← Back to all trials
Completed
NCT05601960
A Combination Treatment Reduces Acne Severity and PIHP
Conditions: Acne, Postinflammatory Hyperpigmentation
Sex: All
Ages: 18 Years – N/A
Enrollment: 1785
Sponsor: Cosmetique Active International
Location: United Arab Emirates
Summary
Acne is a chronic, inflammatory skin condition.
It may cause scars and post-inflammatory hyperpigmentation (PIHP).
PIHP frequently affects individuals with a phototype of IV or above.[1]
PIHP is worsened by UV radiation, lasts for years and impacts the individual well-being.[2,
3] In an observational study, 1785 adults with a phototype ranging from IV to VI with acne and PIHP applied daily for 2 months a dermocosmetic and a tainted sunscreen product (DC, Effaclar® Duo (+); SS, Anthelios® Shaka Fluide SPF 50+, SS; both La Roche-Posay Laboratoire Dermatologique, France.
Eligibility Criteria
Inclusion Criteria:adultmild to moderate acnepresence of postinflammatory hyperpigmentation lesionsphototype IV to VIExclusion Criteria:less than 18 yearssevere acne
Source: ClinicalTrials.gov (NCT05601960). StuddyBuddy aggregates publicly available trial information.
